vTv Therapeutics (VTVT) Accumulated Expenses (2014 - 2015)
vTv Therapeutics (VTVT) reported Accumulated Expenses of $1.0 million for Q4 2015, up 11455.56% on a YoY basis from N/an in Q4 2014, and up 11455.56% sequentially from $9000.0 in Q4 2014.
vTv Therapeutics (VTVT) Accumulated Expenses (2014 - 2015) Analysis & Trends
vTv Therapeutics (VTVT) has 2 years of Accumulated Expenses data on file, last reported at $1.0 million in Q4 2015.
- For the quarter ending Q4 2015, Accumulated Expenses rose 11455.56% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2015 stood at $1.0 million (up 11455.56% YoY), and the FY2015 full-year result was $1.0 million, up 11455.56% from the prior year.
- Accumulated Expenses climbed to $1.0 million in Q4 2015, from $9000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.0 million in Q4 2015 to a low of $9000.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | vTv Therapeutics | 19.21 Mn | 19.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 1.04 Mn |
| Dec 31, 2014 | 9,000.00 |